Vera Therapeutics, Inc. — FY 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. The filing was signed March 26, 2024. This is an annual report, not a quarterly report. Vera is a clinical-stage biotechnology company with no approved products and no product-sales revenue.
Business context and pipeline
- Atacicept: Lead candidate targeting BAFF and APRIL, principally being developed for IgA nephropathy (IgAN). Vera reported positive Phase 2b ORIGIN results at 24 and 36 weeks, and sustained biomarker, proteinuria and kidney-function findings at 72 weeks. The global Phase 3 ORIGIN 3 trial began in 2023.
- Other programs: Vera has designed a Phase 3 atacicept trial for lupus nephritis (LN), but delayed enrollment while prioritizing IgAN. MAU868, a candidate for BK virus infection in kidney transplant recipients, completed Phase 2; the company is evaluating next steps after FDA feedback and deferred resources to the program.
Financial performance and liquidity
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $78.2 million | $69.0 million |
| General and administrative expense | $23.8 million | $21.9 million |
| Total operating expenses | $102.0 million | $90.9 million |
| Net loss | $96.0 million | $89.1 million |
| Net loss per share, basic and diluted | $2.25 | $3.35 |
| Cash used in operating activities | $92.2 million | $67.6 million |
- Cash, cash equivalents and marketable securities totaled $160.7 million at year-end 2023, versus $114.7 million at year-end 2022. Current assets were $172.0 million and current liabilities $22.3 million.
- Year-end debt was $50.0 million principal ($49.9 million net carrying value), versus $25.0 million principal in 2022. The loan bears floating interest subject to an 8.25% floor, includes a 7% final payment fee, and matures in 2027. It is secured by company assets, with intellectual property subject to a negative pledge.
- Operating expenses rose 12%; R&D increased 13%, mainly from atacicept development and manufacturing supply, while G&A increased 9%. Higher interest income partly offset greater operating costs and interest expense. Operating margins are not meaningful because the company has no product revenue.
- In February 2024, after year-end, Vera raised approximately $269.6 million net in a follow-on stock offering. Management stated that year-end liquidity together with these proceeds was expected to fund operations and capital expenditures for at least 12 months from the financial-statement issuance date.
Changes, outlook and key risks
- At 36 weeks in Phase 2b, atacicept 150 mg showed a 43% mean proteinuria reduction versus placebo in a prespecified per-protocol analysis and a 35% difference in the intent-to-treat population; eGFR was stable, Gd-IgA1 fell 64% from baseline, and hematuria resolved in 80% versus 5% on placebo. The open-label 72-week results were described as sustained, but were not a continued blinded placebo comparison.
- Management expected primary-endpoint enrollment in ORIGIN 3 in the second half of 2024, topline results in the first half of 2025 and, if positive, an IgAN BLA submission in the second half of 2025. These are forward-looking targets, not guarantees.
- Atacicept’s prior LN study was terminated after severe hypogammaglobulinemia and pneumonia occurred in participants receiving induction therapy with mycophenolate and corticosteroids. Vera says its planned LN trial design will address dosing and monitoring; enrollment had been delayed.
- The company expects continued losses and additional funding needs. Risks include Phase 3 outcomes and regulatory decisions, trial enrollment and execution, competition, reliance on contract manufacturers and CROs, single-source supply exposure, reimbursement and pricing, and dependence on licensed intellectual property. The filing also identifies potential substantial milestone and royalty obligations under its licenses.
- The filing reports no material legal proceedings. Management concluded disclosure controls and internal control over financial reporting were effective as of year-end; the auditor did not attest to internal-control effectiveness.
Important facts for investors to verify
- ORIGIN 3 enrollment, trial conduct and results against the company’s stated timeline; assess full trial data and the distinction between blinded and open-label findings.
- Whether Phase 3 results support accelerated approval or a BLA, and what confirmatory evidence regulators require.
- Atacicept’s safety, particularly immunoglobulin levels and infection risk in LN combination regimens.
- Updated cash runway, operating burn, debt costs and any further financing or dilution after the February 2024 offering.
- MAU868’s development decision and the scope of future license milestones: the filing’s narrative cites up to $69.0 million of Novartis milestones, while the financial-statement note cites up to $62.0 million.